Illumina Inc (ILMN)

Industry Diagnostics & Research

This stock can be held in an Investment ISA and an Investment Account

Sell

$79.50

Buy

$80.80

arrow-down$-1.27 (-1.56%)

Prices updated at 14 May 2025, 00:58 EDT

Prices minimum 15 mins delay

Prices in USD

Illumina Inc engages in life science tools and machines for analyzing genetic material. The company primarily engages in microarray and genome sequencing machines and disposables. It also provides sequencing services through its products.

NASDAQ

1.61%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Diagnostics & Research

Chairman

Dr. Scott Gottlieb,M.D.

CEO

Mr. Jacob Thaysen

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

8,970

Head office

5200 Illumina Way

San Diego

United States

92122

+1 858 202-4500

ir@illumina.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Keith A. Meister Director	-
Dr. Scott Gottlieb,M.D. Chairman of the board	0.10m
Ms. Caroline D. Dorsa Independent Director	0.10m
Ms. Anna S. Richo Independent Director	0.05m
Dr. Gary S. Guthart,PhD Independent Director	0.10m
Mr. Philip W. Schiller Independent Director	0.10m
Ms. Susan E. Siegel Independent Director	0.10m
Dr. Robert S. Epstein, M.D.,M.S. Independent Director	0.10m
Mr. Scott B. Ullem Independent Director	0.09m
Dr. Frances H. Arnold, PhD Independent Director	0.10m
Mr. Everett V. Cunningham Chief Commercial Officer	0.35m
Mr. Jacob Thaysen Director and Chief Executive Officer	1.00m
Mr. Ankur Dhingra Chief Financial Officer	0.45m
Mr. Kevin Carl Pegels Chief of Global Operations	0.56m
Mr. Scott Ericksen Vice President and Chief Accounting Officer	-
Dr. Steve Barnard, PhD Chief Technology Officer	0.59m
Ms. Patricia Leckman Chief People Officer	-
Mr. Christensen Jakob Wedel Chief Strategy and Corporate Development Officer	-
Mr. Scott M. Davies Chief Legal Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
BlackRock Inc	19,316,617
Capital Research and Management Company	18,389,906
Capital World Investors	18,025,301
Vanguard Group Inc. ( Junked)	15,942,546
Vanguard Group Inc	15,813,419

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2024	-
06 Dec 2024	-
05 Nov 2024	-
05 Nov 2024	-
05 Nov 2024	-
05 Nov 2024	-
05 Nov 2024	-
05 Nov 2024	-
05 Oct 2024	-
30 Sep 2024	-
13 Sep 2024	-
05 Sep 2024	-
15 Aug 2024	-
28 Jun 2024	-
16 May 2024	-
16 May 2024	-
16 May 2024	-
16 May 2024	-
16 May 2024	-
16 May 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.